Study of nonenzymatic glycation of transferrin and its effect on iron-binding antioxidant capacity

Iranian Journal of Basic Medical Sciences

Volumn 13, Issue 4, 2010, Pages 194-199

  Goodarzi, Mohammad Taghi ^a   Rashidi, Mojtaba ^b   Rezaei, Mohsen ^b  

^a HAMADAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b HAMADAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Apotransferrin; Diabetes mellitus; Glycation; Oxidative stress

Indexed keywords

APOTRANSFERRIN; GLUCOSE; SODIUM DIHYDROGEN PHOSPHATE; THIOBARBITURIC ACID; TRANSFERRIN;

ANTIOXIDANT ACTIVITY; ARTICLE; DIABETES MELLITUS; GLYCATION; HEMOLYSIS; HUMAN; OBSERVATION; OXIDATIVE STRESS; PH; STATISTICAL SIGNIFICANCE;

EID: 77957268965     PISSN: 20083866     EISSN: 20083874     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Misciagna G, De Michele G, Trevisan M. Non enzymatic glycated proteins in the blood and cardiovascular disease. Curr Pharm Des 2007; 13:3688-3695.
2. Nakajou K, Watanabe H, Kragh-Hansen U, Maruyama T, Otagiri M. The effect of glycation on the structure, function and biological fate of human serum albumin as revealed by recombinant mutants. Biochim Biophys Acta 2003; 1623:88-97.
3. Kennedy DM, Skillen AW, Self CH. Glycation of monoclonal antibodies impairs their ability to bind antigen. Clin Exp Immunol 1994; 98:245-251.
4. Goodarzi MT, Rezaei M, Piry H, Amiry S. Effect of in vitro glycation of human placental collagen (Type IV) on platelet aggregation. Pak J Biolig Sci 2005; 8:1203-1206.
5. Goodarzi MT, Ghahramany S, Mirmoemeni MH. Glycation of human IgG induces structural alterations leading to changes in interaction with anti-IgG. Iran J Immunol 2005; 2:36-42.
6. Goodarzi MT, Ghahramany S, Mirmoemeni MH. In vitro glycation of human IgG and its effect on interaction with anti-IgG. Iran J Allergy Asthma Immunol 2004; 3:181-187.
7. Hémadi M, Kahn PH, Miquel GEl Hage Chahine JM. Transferrin's mechanism of interaction with receptor 1. Biochemistry 2004; 43:1736-1745.
8. Paez PM, Marta CB, Moreno MB, Soto EF, Pasquini JM. Apotransferrin decreases migration and enhances differentiation of oligodendroglial progenitor cells in an in vitro system. Dev Neurosci 2002; 24:47-58.
9. Gomme PT, McCann KB, Bertolini J. Transferrin: structure, function and potential therapeutic actions. Drug Discov Today 2005; 10:267-273. (Pubitemid 40222220)
10. Van Campenhout A, Van Campenhout C, Lagrou AR, Moorkens G, De Block C, Manuel-y-Keenoy B. Iron-binding antioxidant capacity is impaired in diabetes mellitus. Free Radic Biol Med 2006; 40:1749-1755.
11. Negre-Salvayre A, Coatrieux C, Ingueneau C, Salvayre R. Advanced lipid peroxidation end products in oxidative damage to proteins. Potential role in diseases and therapeutic prospects for the inhibitors. Br J Pharmacol 2008; 153:6-20.
12. Gallou G, Ruelland A, Campion L, Maugendre D, Le Moullec N, Legras B, et al. Increase in thiobarbituric acid-reactive substances and vascular complications in type 2 diabetes mellitus. Diabete Metab 1994: 20:258-264. (Pubitemid 24336884)
13. Gutteridge JM, Rowley DA, Halliwell B. Superoxide-dependent formation of hydroxyl radicals and lipid peroxidation in the presence of iron salts. Detection of 'catalytic' iron and antioxidant activity in extracellular fluids. Biochem J 1982: 206:605-609.
14. Gutteridge JM, Quinlan GJ. Antioxidant protection against organic and inorganic oxygen radicals by normal human plasma: the important primary role for iron-binding and iron-oxidizing proteins. Biochim Biophys Acta 1992; 1159:248-254.
15. Huebschmann AG, Regensteiner JG, Vlassara H, Reusch JEB. Diabetic and advanced glycoxidation end products. Diabetes Care 2006; 29:1420-1432. (Pubitemid 44125953)
16. Martin Gallaǹ P, Carrascosa A, Gussinyè M, Dominguez C. Biomarkers of diabetes-associated oxidative stress and antioxidant status in young diabetic patients with or without subclinical complications. Free Radic Biol Med 2003; 34:1563-1574.
17. Breuer W, Hershko C, Cabantchik ZI. The importance of nontransferrin bound iron in disorders of iron metabolism. Transfus Sci 2000; 23:185-192.
18. Van Campenhout A, Van Campenhout CM, Lagrou AR, Manuel-y-Keenoy B. Transferrin modifications and lipid peroxidation: implications in diabetes mellitus. Free Radic Res 2003; 37:1069-1077. (Pubitemid 37265329)
19. Gallou G, Ruelland A, Campion L, Maugendre D, Le Moullec N, Legras B, et al. Increase in thiobarbituric acid-reactive substances and vascular complications in type 2 diabetes mellitus. Diabete Metab 1994; 20:258-264.
20. Koga T, Keiko M, Terao J. Protective effet of vitamin E analog, phosphatidylchromanol, against oxidative hemolysis of human erythrocytes. Lipids 1980; 33:589-595.
21. Valkonen M, Kuusi T. Spectrophotometer assay for total peroxyl radical-trapping antioxidant potential in human serum. J Lipid Res 1997; 38:823-833. (Pubitemid 27194933)
22. Sen S, Kar M, Roy A, Chakraborti AS. Effect of nonenzymatic glycation on function and structural properties of hemoglobin. Biophys Chem 2005; 113:289-298. (Pubitemid 40037809)
23. Fujimoto S, Kawakami N, Ohara A. Nonenzymatic glycation of transferri: decrease of iron-binding capacity and increase of oxygen radical production. Biol Pharm Bull 1995; 18:396-400.
24. 3+ isoforms of transferrin. Clin Chem 2004; 50: 1640-1649.
25. Van Campenhout A, Van Campenhout C, Olyslager YS, Van Damme O, Lagrou AR, Manuel-y-Keenoy B. A novel method to quantify in vivo transferrin glycation: application in diabetes mellitus. Clin Chim Acta 2006; 370:115-123.